enGene (ENGN) Stock: Buy, Sell, or Hold?
ENGN - enGene Holdings Inc. Common Stock
$1.56
-0.02 (-1.27%)
▼
5d:
-6.59%
30d:
-18.75%
90d:
-11.36%
HOLD
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Sep 10, 2026
0d
Get Alerted When ENGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ENGN shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ENGN shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ENGN is currently trading at $1.56, which is considered slightly low relative to its 30-day fair value range of $1.70 to $1.97.
Technical Outlook: Technically, ENGN is showing sideways momentum. The price is currently testing key support at $1.54. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ENGN scores 70/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $3.29 (+110.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ENGN is showing sideways momentum. The price is currently testing key support at $1.54. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ENGN scores 70/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $3.29 (+110.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$1.70 -
$1.97
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
94.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (70/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 110.6% below Wall St target ($3.29)
- BULLISH: Bottoming setup score 70/100 — corrected, stabilizing, and turning up
- CAUTION: Recommendation downgraded due to -6.6% 5-day decline
Trading Range Analysis
30-Day Trading Range
$1.70 -
$1.97
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$1.54
Resistance Level
$1.75
Current Trend
Sideways
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.03
Wall Street Target
$3.29
(+110.6%)
Share & Embed Analysis
Last updated: October 24, 2026 12:49 AM ET
Data refreshes hourly during market hours. Next update: 1:49 AM
Data refreshes hourly during market hours. Next update: 1:49 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ENGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
22 analysts |
$295 | 64 BUY |
|
PRAX
Praxis Precision Medicin… |
STRONG BUY
20 analysts |
$650 | 65 BUY |
|
REGN
Regeneron Pharmaceutical… |
BUY
28 analysts |
$864 | 35 SELL |
|
ELVN
Enliven Therapeutics Inc. |
STRONG BUY
14 analysts |
$74 | 65 BUY |
|
ACAD
ACADIA Pharmaceuticals I… |
STRONG BUY
20 analysts |
$31 | 61 BUY |
